当前位置: 首页 >> 检索结果
3301. Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most?
The expense of new therapies for HCV infection may force health systems to prioritise the treatment of certain patient groups over others. Our objective was to forecast the population impact of possible prioritisation strategies for the resource-rich setting of Scotland.
3303. Early-onset Crohn's disease and autoimmunity associated with a variant in CTLA-4.
作者: Sebastian Zeissig.;Britt-Sabina Petersen.;Michal Tomczak.;Espen Melum.;Emilie Huc-Claustre.;Stephanie K Dougan.;Jon K Laerdahl.;Björn Stade.;Michael Forster.;Stefan Schreiber.;Dascha Weir.;Alan M Leichtner.;Andre Franke.;Richard S Blumberg.
来源: Gut. 2015年64卷12期1889-97页
IBD is a group of complex, systemic disorders associated with intestinal inflammation and extraintestinal manifestations. Recent studies revealed Mendelian forms of IBD, which contributed significantly to our understanding of disease pathogenesis and the heritability of IBD.
3304. Reproducibility of histological assessments of disease activity in UC.
作者: Mahmoud H Mosli.;Brian G Feagan.;Guangyong Zou.;William J Sandborn.;Geert D'Haens.;Reena Khanna.;Cynthia Behling.;Keith Kaplan.;David K Driman.;Lisa M Shackelton.;Kenneth A Baker.;John K MacDonald.;Margaret K Vandervoort.;Mark A Samaan.;Karel Geboes.;Mark A Valasek.;Rish Pai.;Cord Langner.;Robert Riddell.;Noam Harpaz.;Maida Sewitch.;Michael Peterson.;Larry W Stitt.;Barrett G Levesque.
来源: Gut. 2015年64卷11期1765-73页
Histopathology is potentially an important outcome measure in UC. Multiple histological disease activity (HA) indices, including the Geboes score (GS) and modified Riley score (MRS), have been developed; however, the operating properties of these instruments are not clearly defined. We assessed the reproducibility of existing measures of HA.
3306. Causes of death in people with coeliac disease in England compared with the general population: a competing risk analysis.
作者: Alyshah Abdul Sultan.;Colin J Crooks.;Tim Card.;Laila J Tata.;Kate M Fleming.;Joe West.
来源: Gut. 2015年64卷8期1220-6页
Quantifying excess cause-specific mortality among people with coeliac disease (CD) compared with the general population accounting for competing risks will allow accurate information to be given on risk of death from specific causes.
3308. A rare cause of abdominal pain, diarrhoea and GI bleeding. Idiopathic myointimal hyperplasia of the mesenteric veins (IMHMV).
作者: Faidon-Marios Laskaratos.;Mark Hamilton.;Marco Novelli.;Neil Shepherd.;Gareth Jones.;Christopher Lawrence.;Miriam Mitchison.;Charles D Murray.
来源: Gut. 2015年64卷2期214, 350页 3309. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease.
作者: Niels Vande Casteele.;Reena Khanna.;Barrett G Levesque.;Larry Stitt.;G Y Zou.;Sharat Singh.;Steve Lockton.;Scott Hauenstein.;Linda Ohrmund.;Gordon R Greenberg.;Paul J Rutgeerts.;Ann Gils.;William J Sandborn.;Séverine Vermeire.;Brian G Feagan.
来源: Gut. 2015年64卷10期1539-45页
Although low infliximab trough concentrations and antibodies to infliximab (ATI) are associated with poor outcomes in patients with Crohn's disease (CD), the clinical relevance of ATI in patients with adequate infliximab concentrations is uncertain. We evaluated this question using an assay sensitive for identification of ATI in the presence of infliximab.
3310. SOX9 regulates ERBB signalling in pancreatic cancer development.
作者: Adrien Grimont.;Andreia V Pinho.;Mark J Cowley.;Cécile Augereau.;Amanda Mawson.;Marc Giry-Laterrière.;Géraldine Van den Steen.;Nicola Waddell.;Marina Pajic.;Christine Sempoux.;Jianmin Wu.;Sean M Grimmond.;Andrew V Biankin.;Frédéric P Lemaigre.;Ilse Rooman.;Patrick Jacquemin.
来源: Gut. 2015年64卷11期1790-9页
The transcription factor SOX9 was recently shown to stimulate ductal gene expression in pancreatic acinar-to-ductal metaplasia and to accelerate development of premalignant lesions preceding pancreatic ductal adenocarcinoma (PDAC). Here, we investigate how SOX9 operates in pancreatic tumourigenesis.
3317. Global incidence of oesophageal cancer by histological subtype in 2012.
The two major histological types of oesophageal cancer--adenocarcinoma (AC) and squamous cell carcinoma (SCC)--are known to differ greatly in terms of risk factors and epidemiology. To date, global incidence estimates for individual subtypes are still lacking. This study for the first time quantified the global burden of oesophageal cancer by histological subtype.
3318. Acute kidney injury and acute-on-chronic liver failure classifications in prognosis assessment of patients with acute decompensation of cirrhosis.
作者: Paolo Angeli.;Ezequiel Rodríguez.;Salvatore Piano.;Xavier Ariza.;Filippo Morando.;Elsa Solà.;Antonietta Romano.;Elisabet García.;Marco Pavesi.;Alessandro Risso.;Alexander Gerbes.;Chris Willars.;Mauro Bernardi.;Vicente Arroyo.;Pere Ginès.; .
来源: Gut. 2015年64卷10期1616-22页
Prognostic stratification of patients with cirrhosis is common clinical practice. This study compares the prognostic accuracy (28-day and 90-day transplant-free mortality) of the acute-on-chronic liver failure (ACLF) classification (no ACLF, ACLF grades 1, 2 and 3) with that of acute kidney injury (AKI) classification (no AKI, AKI stages 1, 2 and 3).
3319. Authors' response to the letter: Liver resection for patients with hepatocellular carcinoma and macrovascular invasion, multiple tumours or portal hypertension by Zhong et al.3320. Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C.
作者: Ramón San Miguel.;Vicente Gimeno-Ballester.;Antonio Blázquez.;Javier Mar.
来源: Gut. 2015年64卷8期1277-88页
A new scenario of therapy for chronic hepatitis C (CHC) is being established with the approval of sofosbuvir (SOF).
|